ArticleNature nanotechnology2014
Detection of cancer biomarkers in serum using a hybrid mechanical and optoplasmonic nanosensor.
Article in Nature nanotechnology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed.
- An Integrated Hardware-Software Platform for Automated Thermodynamic Characterization of Gas-Solid Interfaces Using a Resonant Microcantilever.Micromachines · 2026Article
- Efficient Mapping and Tracking the Properties of Micromechanical Resonators Using Phase-Lock Loops with Closely-Spaced Frequencies.Micromachines · 2026Article
- Review
- Biosensors, Artificial Intelligence Biosensors, False Results and Novel Future Perspectives.Diagnostics (Basel, Switzerland) · 2025Review
- Introducing AVAC as an ultra-sensitive platform with broad dynamical range for high-throughput multiplexed biomarker detection using digital counting of plasmonic nanoparticles.Scientific reports · 2025Article
- Nanomechanical detection to empower robust monitoring of sepsis and microbial adaptive immune system-mediated proinflammatory disease.Scientific reports · 2024Article
- Mass and Stiffness Deconvolution in Nanomechanical Resonators for Precise Mass Measurement and In Vivo Biosensing.ACS nano · 2024Article
- Nano-bio-interface: Unleashing the Potential of Noble Nanometals.Small science · 2024Article
- Ultrasensitive detection of vital biomolecules based on a multi-purpose BioMEMS for Point of care testing: digoxin measurement as a case study.Scientific reports · 2024Article
- Immobilization of azide-functionalized proteins to micro- and nanoparticles directly from cell lysate.Mikrochimica acta · 2023Article
- Nanomechanical Photothermal Near Infrared Spectromicroscopy of Individual Nanorods.ACS photonics · 2023Article
- NIR-II Imaging and Sandwiched Plasmonic Biosensor for Ultrasensitive Intraoperative Definition of Tumor-Invaded Lymph Nodes.Nano letters · 2023Article
- Hemolysis-Inspired, Highly Sensitive, Label-Free IgM Detection Using Erythrocyte Membrane-Functionalized Nanomechanical Resonators.Materials (Basel, Switzerland) · 2022Article
- Recent Advances in Nanomechanical Membrane-Type Surface Stress Sensors towards Artificial Olfaction.Biosensors · 2022Review
- Nanosensor Applications in Plant Science.Biosensors · 2022Review
- Ultrasensitive Detection of Biomarkers in a Color-Switchable Microcavity-Reactor Laser.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Article
- High-Property Refractive Index and Bio-Sensing Dual-Purpose Sensor Based on SPPs.Micromachines · 2022Article
- A Sensitivity-Enhanced Electrolyte-Gated Graphene Field-Effect Transistor Biosensor by Acoustic Tweezers.Micromachines · 2021Article
- Hollow mesoporous MnOMikrochimica acta · 2021Article
- Role of plasmonics in detection of deadliest viruses: a review.European physical journal plus · 2021Review
3 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Blood contains a range of protein biomarkers that could be used in the early detection of disease. To achieve this, however, requires sensors capable of detecting (with high reproducibility) biomarkers at concentrations one million times lower than the concentration of the other blood proteins. Here, we show that a sandwich assay that combines mechanical and optoplasmonic transduction can detect cancer biomarkers in serum at ultralow concentrations. A biomarker is first recognized by a surface-anchored antibody and then by an antibody in solution that identifies a free region of the captured biomarker. This second antibody is tethered to a gold nanoparticle that acts as a mass and plasmonic label; the two signatures are detected by means of a silicon cantilever that serves as a mechanical resonator for 'weighing' the mass of the captured nanoparticles and as an optical cavity that boosts the plasmonic signal from the nanoparticles. The capabilities of the approach are illustrated with two cancer biomarkers: the carcinoembryonic antigen and the prostate specific antigen, which are currently in clinical use for the diagnosis, monitoring and prognosis of colon and prostate cancer, respectively. A detection limit of 1 × 10(-16) g ml(-1) in serum is achieved with both biomarkers, which is at least seven orders of magnitude lower than that achieved in routine clinical practice. Moreover, the rate of false positives and false negatives at this concentration is extremely low, ∼10(-4).
Indexed as
Identifiers
25362477What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.